HCA Healthcare (NYSE:HCA) Price Target Raised to $430.00

HCA Healthcare (NYSE:HCA) had its price target upped by Truist Financial from $390.00 to $430.00 in a research note issued to investors on Monday morning, Benzinga reports. Truist Financial currently has a buy rating on the stock.

Other equities research analysts have also issued research reports about the company. Oppenheimer boosted their price target on HCA Healthcare from $345.00 to $390.00 and gave the stock an outperform rating in a research note on Wednesday, July 24th. Barclays raised their price target on HCA Healthcare from $376.00 to $396.00 and gave the company an overweight rating in a research report on Wednesday, July 24th. Robert W. Baird began coverage on shares of HCA Healthcare in a research note on Thursday, May 30th. They issued an outperform rating and a $396.00 price objective on the stock. UBS Group increased their price target on shares of HCA Healthcare from $405.00 to $438.00 and gave the company a buy rating in a research report on Wednesday, August 14th. Finally, StockNews.com raised HCA Healthcare from a buy rating to a strong-buy rating in a research note on Monday, July 1st. Four equities research analysts have rated the stock with a hold rating, fourteen have given a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, HCA Healthcare has a consensus rating of Moderate Buy and an average price target of $354.67.

HCA Healthcare Price Performance

Shares of NYSE:HCA opened at $376.62 on Monday. The company has a market cap of $98.64 billion, a P/E ratio of 18.77, a PEG ratio of 1.39 and a beta of 1.68. The company has a 50-day moving average price of $342.60 and a 200 day moving average price of $329.87. HCA Healthcare has a 52 week low of $215.96 and a 52 week high of $379.52. The company has a quick ratio of 0.94, a current ratio of 1.06 and a debt-to-equity ratio of 27.11.

HCA Healthcare (NYSE:HCA) last released its quarterly earnings data on Tuesday, July 23rd. The company reported $5.50 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.97 by $0.53. The firm had revenue of $17.49 billion during the quarter, compared to analysts’ expectations of $17.05 billion. HCA Healthcare had a return on equity of 553.13% and a net margin of 8.40%. HCA Healthcare’s revenue was up 10.3% compared to the same quarter last year. During the same quarter in the prior year, the business posted $4.29 earnings per share. Research analysts predict that HCA Healthcare will post 22.43 earnings per share for the current year.

HCA Healthcare Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, September 30th. Stockholders of record on Monday, September 16th will be given a dividend of $0.66 per share. This represents a $2.64 dividend on an annualized basis and a dividend yield of 0.70%. The ex-dividend date of this dividend is Monday, September 16th. HCA Healthcare’s payout ratio is 13.16%.

Insider Buying and Selling at HCA Healthcare

In other news, SVP Kathryn A. Torres sold 1,857 shares of the firm’s stock in a transaction that occurred on Thursday, July 25th. The shares were sold at an average price of $355.05, for a total transaction of $659,327.85. Following the completion of the sale, the senior vice president now owns 17,755 shares of the company’s stock, valued at $6,303,912.75. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In related news, SVP Kathleen M. Whalen sold 2,987 shares of the company’s stock in a transaction that occurred on Wednesday, July 31st. The stock was sold at an average price of $363.51, for a total transaction of $1,085,804.37. Following the sale, the senior vice president now directly owns 9,454 shares of the company’s stock, valued at approximately $3,436,623.54. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, SVP Kathryn A. Torres sold 1,857 shares of the stock in a transaction on Thursday, July 25th. The stock was sold at an average price of $355.05, for a total transaction of $659,327.85. Following the sale, the senior vice president now directly owns 17,755 shares in the company, valued at $6,303,912.75. The disclosure for this sale can be found here. Insiders sold a total of 8,844 shares of company stock worth $3,185,932 in the last 90 days. 1.60% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On HCA Healthcare

Institutional investors and hedge funds have recently bought and sold shares of the business. MFA Wealth Advisors LLC bought a new stake in shares of HCA Healthcare in the 2nd quarter worth approximately $27,000. Unique Wealth Strategies LLC acquired a new position in shares of HCA Healthcare during the second quarter valued at $28,000. Bangor Savings Bank increased its holdings in shares of HCA Healthcare by 112.5% in the 2nd quarter. Bangor Savings Bank now owns 85 shares of the company’s stock worth $27,000 after acquiring an additional 45 shares during the period. GPS Wealth Strategies Group LLC boosted its stake in HCA Healthcare by 284.0% during the 2nd quarter. GPS Wealth Strategies Group LLC now owns 96 shares of the company’s stock valued at $31,000 after purchasing an additional 71 shares during the period. Finally, Atlantic Edge Private Wealth Management LLC bought a new stake in shares of HCA Healthcare during the fourth quarter valued at approximately $27,000. Institutional investors and hedge funds own 62.73% of the company’s stock.

HCA Healthcare Company Profile

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.